Barclays analyst Gena Wang raised the firm’s price target on Cellectis (CLLS) to $8 from $4 and keeps an Overweight rating on the shares. The company’s research and development day provided updates on lasme-cel’s “promising” efficacy data, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS: